Fusion biopsy combines magnetic resonance imaging (MRI) and ultrasound-guided biopsy to identify abnormalities in the prostate. It provides improved visualization of the prostate as compared to ultrasound alone. The technique helps urologists target suspicious areas for biopsy that may not be detected by conventional biopsy alone. This allows for fewer, yet more targeted samples to be taken from the prostate, reducing the chances of missing cancer and minimizing unnecessary biopsies in men who do not have prostate cancer.

The Global Fusion Biopsy Market is estimated to be valued at USD 791.1 Mn in 2025 and is expected to reach USD 1,418.2 Mn by 2032, exhibiting a compound annual growth rate (CAGR) of 8.7% from 2025 to 2032.

The growing Fusion Biopsy Market Demand for minimally invasive procedures for prostate biopsy is supporting the growth of the fusion biopsy market. Fusion biopsy allows for fewer samples to be taken from the prostate, reducing patient discomfort, and decreasing the risks associated with repeated biopsies.

Get More Insights On- Fusion Biopsy Market